title: Effect of the progesterone antagonist RU486 on human myometrial spontaneous contractility and PGI2 release.
abstract: We studied the effect of antiprogesterone RU 486 on spontaneous uterine contractility and PGI2 release with human myometrial strips superfused "in vitro". A decrease of PGI2 release into the superfusion medium was observed after 20 min superfusion. The inhibition was dose-dependent and reversible. After 20 min washing with tyrode medium without RU 486, the uterine strips recovered their initial rate of release. R5020, a progesterone agonist, did not affect PGI2 release nor dexamethasone and testosterone. Parallel to the decrease of PGI2 observed during RU 486 superfusion, the uterine spontaneous contraction frequency decreased, while the amplitude and duration of contractions increased. The alteration of uterine contractility was also rapid, dose-dependent and reversible. Modification of uterine strip spontaneous contractility, similar to those induced by RU 486, were also observed with superfusions of R5020 at concentrations as low as 10(-9)M, dexamethasone (10(-8)M), but not with superfusions of testosterone. These observations are not in favour of a progesterone-receptor mediated effect of RU 486 in our model. The mechanism of action may be related to the antiprogesterone specific structure i.e. the bulky substituent at the C-11 position. The RU 486 effect on uterine strip contractility, mimicked by other steroids, could point to a non-specific lipid/membrane interaction. However, the fact that testosterone did not affect motility, may indicate a possible specificity of steroids having a 3 oxo pregnene structure.
authors: Unite 58 I.N.S.E.R.M., Montpellier, France.
authors: C
authors: C
authors: Lobaccaro-Henri
authors: M
authors: M
authors: Saintot
authors: F
authors: F
authors: Laffargue
authors: H P
authors: HP
authors: Zahradnik
authors: B
authors: B
authors: Descomps
authors: H
authors: H
authors: Thaler-Dao
mesh_terms: D000328:Adult; D003907:Dexamethasone / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D011464:Epoprostenol / Q000378:metabolism*; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D015735:Mifepristone / Q000494:pharmacology*; D009215:Myometrium / Q000187:drug effects; D011397:Promegestone / Q000494:pharmacology; D011460:Prostaglandins F / Q000378:metabolism; D014590:Uterine Contraction / Q000187:drug effects*
chemical_list: D011460:Prostaglandins F; D015735:Mifepristone; D003907:Dexamethasone; D011397:Promegestone; D011464:Epoprostenol; C100006:prostaglandin F1